Nienke van Rein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nienke van Rein has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Felix J. M. van der Meer
Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
6 shared publications- Suzanne C. Cannegieter
Department of Clinical Epidemiology Leiden University Medical Center Leiden the Netherlands
6 shared publications Willem M. Lijfering
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
6 shared publicationsPieter H. Reitsma
Division of Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands
5 shared publicationsSuzanne C. Cannegieter
Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, the Netherlands
3 shared publications- Eleonora Camilleri
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 11 October 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10)
Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022)
Objectives: To describe temporal trends in the clinical landscape of vitamin K antagonist (VKA) treatment in the Netherlands, after the introduction of a lower international normalized ratio (INR) target range in 2016 and direct oral anticoagulants. Methods: Data from 17 Dutch anticoagulation clinics between 2014 and 2022 were individually linked to nationwide healthcare data. Prevalent VKA users were identified on January 1 of each year, forming nine annual cohorts. We assessed baseline patient characteristics, anticoagulation treatment quality (using time in/above/below therapeutic range [TTR/ATR/BTR]), and annual odds ratios of major bleeding and thromboembolism for each cohort. Results: The number of patients treated with VKAs increased from 101 090 in 2014 to 121 916 in 2017, followed by a decline to 73 649 in 2022. Over time, cohorts were characterized by increasing age and a higher prevalence of comorbidities, with a doubling of kidney disease. After the introduction of the lower INR target range, mean BTR decreased (~30% in 2014 to ~15% in 2022), while mean TTR increased (~54% in 2014 to ~67% in 2022), with stable mean ATR. Across calendar years, the 1‐year odds ratio of major bleeding decreased from 1.71% (95% CI 1.63–1.79) in 2014 to 1.52% (95% CI 1.44–1.61) in 2022, whereas the odds ratio of ischemic stroke/transient ischemic attack/systemic thromboembolism increased from 1.14% (95% CI 1.08–1.21) in 2014 to 1.32% (95% CI 1.24–1.40) in 2022. The 1‐year odds ratio of mortality increased from 5.09 (95% CI 4.95–5.22) to 8.55 (95% CI 8.35–8.75), with an OR of 1.74 (95% CI 1.68–1.81). Conclusions: VKA users declined between 2014 and 2022. The remaining patients using VKA became older and more comorbid. During this period, INR target ranges were lowered, while temporal changes were observed with decreasing odds ratio of major bleeding and increasing odds ratio of thromboembolism and mortality.
- 11 October 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10)
Open AccessTemporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022)
Objectives: To describe temporal trends in the clinical landscape of vitamin K antagonist (VKA) treatment in the Netherlands, after the introduction of a lower international normalized ratio (INR) target range in 2016 and direct oral anticoagulants. Methods: Data from 17 Dutch anticoagulation clinics between 2014 and 2022 were individually linked to nationwide healthcare data. Prevalent VKA users were identified on January 1 of each year, forming nine annual cohorts. We assessed baseline patient characteristics, anticoagulation treatment quality (using time in/above/below therapeutic range [TTR/ATR/BTR]), and annual odds ratios of major bleeding and thromboembolism for each cohort. Results: The number of patients treated with VKAs increased from 101 090 in 2014 to 121 916 in 2017, followed by a decline to 73 649 in 2022. Over time, cohorts were characterized by increasing age and a higher prevalence of comorbidities, with a doubling of kidney disease. After the introduction of the lower INR target range, mean BTR decreased (~30% in 2014 to ~15% in 2022), while mean TTR increased (~54% in 2014 to ~67% in 2022), with stable mean ATR. Across calendar years, the 1‐year odds ratio of major bleeding decreased from 1.71% (95% CI 1.63–1.79) in 2014 to 1.52% (95% CI 1.44–1.61) in 2022, whereas the odds ratio of ischemic stroke/transient ischemic attack/systemic thromboembolism increased from 1.14% (95% CI 1.08–1.21) in 2014 to 1.32% (95% CI 1.24–1.40) in 2022. The 1‐year odds ratio of mortality increased from 5.09 (95% CI 4.95–5.22) to 8.55 (95% CI 8.35–8.75), with an OR of 1.74 (95% CI 1.68–1.81). Conclusions: VKA users declined between 2014 and 2022. The remaining patients using VKA became older and more comorbid. During this period, INR target ranges were lowered, while temporal changes were observed with decreasing odds ratio of major bleeding and increasing odds ratio of thromboembolism and mortality.
- Open Access
- 2 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (28) , 2809-2821
Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015–22): sex differences and shifts during the coronavirus disease 2019 pandemic
Background and Aims: Epidemiology of pulmonary embolism (PE) may have shifted since the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to describe temporal trends in PE epidemiology in the Netherlands since 2015. Methods: Using nationwide data from Statistics Netherlands, all Dutch inhabitants (>16 million) without a history of PE were dynamically identified on 1 January of each year to assemble eight cohorts of PE-free Dutch inhabitants in 2015–22. They were individually followed until the end of that respective year to determine 1-year risk of PE (identified by hospital diagnoses/primary cause of death) and establish relevant risk factors. The PE cases were subsequently studied to determine 1-year all-cause mortality following PE. Multivariable logistic regression with cluster-robust standard errors and robust Poisson regression were respectively employed to evaluate relative differences in PE incidence and mortality between years. Results: Pulmonary embolism incidence in the Dutch population decreased from 2015 to 2019 but markedly increased by 23% (95% confidence interval 20%–26%), 52% (48%–56%), and 7% (4%–9%) in 2020–22 (vs. 2019), respectively. Most traditional PE risk factors remained associated with PE in 2020–22 but generally with a weaker association. Pulmonary embolism mortality was stable until 2019 but then increased by 10% (6%–14%) in 2020 and 9% (6%–13%) in 2021, while the increase [2% (−1% to 6%)] was insignificant in 2022. The above-mentioned changes since 2020 were generally greater in males than females. Conclusions: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.
- 2 April 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (28) , 2809-2821
Open AccessIncidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015–22): sex differences and shifts during the coronavirus disease 2019 pandemic
Background and Aims: Epidemiology of pulmonary embolism (PE) may have shifted since the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to describe temporal trends in PE epidemiology in the Netherlands since 2015. Methods: Using nationwide data from Statistics Netherlands, all Dutch inhabitants (>16 million) without a history of PE were dynamically identified on 1 January of each year to assemble eight cohorts of PE-free Dutch inhabitants in 2015–22. They were individually followed until the end of that respective year to determine 1-year risk of PE (identified by hospital diagnoses/primary cause of death) and establish relevant risk factors. The PE cases were subsequently studied to determine 1-year all-cause mortality following PE. Multivariable logistic regression with cluster-robust standard errors and robust Poisson regression were respectively employed to evaluate relative differences in PE incidence and mortality between years. Results: Pulmonary embolism incidence in the Dutch population decreased from 2015 to 2019 but markedly increased by 23% (95% confidence interval 20%–26%), 52% (48%–56%), and 7% (4%–9%) in 2020–22 (vs. 2019), respectively. Most traditional PE risk factors remained associated with PE in 2020–22 but generally with a weaker association. Pulmonary embolism mortality was stable until 2019 but then increased by 10% (6%–14%) in 2020 and 9% (6%–13%) in 2021, while the increase [2% (−1% to 6%)] was insignificant in 2022. The above-mentioned changes since 2020 were generally greater in males than females. Conclusions: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.
- Open Access
- 30 April 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (6) , 416-424
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort
Background: Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk.Aim: To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma‐glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit‐1 (VKORC1).Methods: A case‐cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow‐up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression.Results: Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2‐TT carriership was associated with a 1.6‐fold (95% CI 0.9–2.8) increased risk of major bleeding compared with CC‐alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2‐TT, and VKORC1‐AA was associated with a 4.0‐fold (95%CI 1.4–11.4) increased risk, while carriers of both CYP4F2‐TT and VKORC1‐AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5–29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively).Conclusions: CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
- 30 April 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (6) , 416-424
Open AccessGenetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort
Background: Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk.Aim: To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma‐glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit‐1 (VKORC1).Methods: A case‐cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow‐up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression.Results: Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2‐TT carriership was associated with a 1.6‐fold (95% CI 0.9–2.8) increased risk of major bleeding compared with CC‐alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2‐TT, and VKORC1‐AA was associated with a 4.0‐fold (95%CI 1.4–11.4) increased risk, while carriers of both CYP4F2‐TT and VKORC1‐AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5–29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively).Conclusions: CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
- Open Access
- 8 October 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 123 (02) , 245-254
Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
Background Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition. Aims To determine whether SSRIs are associated with major bleeding during VKA treatment and investigate the possible mechanisms. Methods In this cohort study, information on SSRI use and bleeding complications was obtained from patient records of VKA initiators between 2006 and 2018 from two anticoagulation clinics. Conditional logistic regression and time-dependent Cox regression were used to estimate the effect of SSRIs on a high international normalized ratio (INR ≥ 5) within 2 months after SSRI initiation and on major bleeding during the entire period of SSRI use, respectively. SSRI use was stratified for (non-)CYP2C9 inhibitors. Results A total of 58,918 patients were included, of whom 1,504 were SSRI users. SSRI initiation versus nonuse was associated with a 2.41-fold (95% confidence interval [CI]: 2.01–2.89) increased risk for a high INR, which was 3.14-fold (95% CI: 1.33–7.43) among CYP2C9-inhibiting SSRI users. The adjusted hazard ratio of major bleeding was 1.22 (95% CI: 0.99–1.50) in all SSRI users and 1.31 (95% CI: 0.62–2.72) in CYP2C9-inhibiting SSRI users compared with nonusers. Conclusion SSRI use is associated with an increased risk of high INR and might be associated with major bleeding. The risk of a high INR was slightly more elevated for CYP2C9-inhibiting SSRI users, suggesting there might be a pharmacokinetic interaction (by CYP2C9 inhibition) next to a pharmacodynamic effect of SSRIs on platelet activation. S.B. and J.L.I.B. contributed equally to this article. N.vR., S.B., J.L.I.B., and W.M.L. designed the research. M.J.H.A.K. and F.J.M.vdM. provided data from the anticoagulation clinics. S.B., J.L.I.B., and N.vR. analyzed the data. S.B. and J.L.I.B. wrote the first manuscript draft. J.L.I.B. and N.vR. revised the manuscript. All authors gave final approval of the version to be published. The deidentified data that support the findings of this study are available from the corresponding author upon reasonable request. * These authors contributed equally to the manuscript. Received: 01 June 2022 Accepted: 29 September 2022 Accepted Manuscript online: 08 October 2022 Article published online: 30 December 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 8 October 2022
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 123 (02) , 245-254
Open AccessSelective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
Background Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition. Aims To determine whether SSRIs are associated with major bleeding during VKA treatment and investigate the possible mechanisms. Methods In this cohort study, information on SSRI use and bleeding complications was obtained from patient records of VKA initiators between 2006 and 2018 from two anticoagulation clinics. Conditional logistic regression and time-dependent Cox regression were used to estimate the effect of SSRIs on a high international normalized ratio (INR ≥ 5) within 2 months after SSRI initiation and on major bleeding during the entire period of SSRI use, respectively. SSRI use was stratified for (non-)CYP2C9 inhibitors. Results A total of 58,918 patients were included, of whom 1,504 were SSRI users. SSRI initiation versus nonuse was associated with a 2.41-fold (95% confidence interval [CI]: 2.01–2.89) increased risk for a high INR, which was 3.14-fold (95% CI: 1.33–7.43) among CYP2C9-inhibiting SSRI users. The adjusted hazard ratio of major bleeding was 1.22 (95% CI: 0.99–1.50) in all SSRI users and 1.31 (95% CI: 0.62–2.72) in CYP2C9-inhibiting SSRI users compared with nonusers. Conclusion SSRI use is associated with an increased risk of high INR and might be associated with major bleeding. The risk of a high INR was slightly more elevated for CYP2C9-inhibiting SSRI users, suggesting there might be a pharmacokinetic interaction (by CYP2C9 inhibition) next to a pharmacodynamic effect of SSRIs on platelet activation. S.B. and J.L.I.B. contributed equally to this article. N.vR., S.B., J.L.I.B., and W.M.L. designed the research. M.J.H.A.K. and F.J.M.vdM. provided data from the anticoagulation clinics. S.B., J.L.I.B., and N.vR. analyzed the data. S.B. and J.L.I.B. wrote the first manuscript draft. J.L.I.B. and N.vR. revised the manuscript. All authors gave final approval of the version to be published. The deidentified data that support the findings of this study are available from the corresponding author upon reasonable request. * These authors contributed equally to the manuscript. Received: 01 June 2022 Accepted: 29 September 2022 Accepted Manuscript online: 08 October 2022 Article published online: 30 December 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 20 September 2022
- Published by Wiley in Journal of Internal Medicine
- Vol. 293 (1) , 124-127
Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
- 20 September 2022
- Published by Wiley in Journal of Internal Medicine
- Vol. 293 (1) , 124-127
Open AccessAssociation of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (2) , 114-125
Nonsustained Ventricular Tachycardia Is Independently Associated With Sustained Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy
Background: Spontaneous nonsustained ventricular tachycardia (NSVT) on Holter, VT inducibility during electrophysiology study, and late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) have been associated with sustained ventricular arrhythmias (SVAs) in nonischemic dilated cardiomyopathy (DCM). This study aimed to analyze whether these parameters carry independent prognostic value for spontaneous SVA in DCM. Methods: Between 2011 and 2018, patients with the DCM clinical spectrum and documented SVA, suspected SVA, or considered to be at intermediate or high risk for SVA were enrolled in the prospective Leiden Nonischemic Cardiomyopathy Study. Patients underwent a comprehensive evaluation including 24-hour Holter, LGE-CMR, and electrophysiology study. Holters were assessed for the presence of NSVT (≥3 beats; rate, ≥120 bpm; lasting 0.05). During 4.0±1.8 years of follow-up, SVA occurred in 39 patients (34%). NSVT (HR, 4.47 [95% CI, 1.87–10.72]; P =0.001) and VT inducibility (HR, 3.08 [95% CI, 1.08–8.81]; P =0.036) were independently associated with SVA during follow-up. A bivariable model including only noninvasively acquired parameters also allowed identification of a high-risk subgroup (ie, those with both NSVT and LGE on CMR). The findings remained similar when only patients without prior SVA were included. Conclusions: In patients with DCM, NSVT on Holter and VT inducibility during electrophysiology study predict SVA during follow-up independent of LGE on CMR. NSVTs may serve as an initiator, and sustained VT inducibility indicates the presence of the substrate for SVA in DCM. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01940081.
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (2) , 114-125
Nonsustained Ventricular Tachycardia Is Independently Associated With Sustained Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy
Background: Spontaneous nonsustained ventricular tachycardia (NSVT) on Holter, VT inducibility during electrophysiology study, and late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) have been associated with sustained ventricular arrhythmias (SVAs) in nonischemic dilated cardiomyopathy (DCM). This study aimed to analyze whether these parameters carry independent prognostic value for spontaneous SVA in DCM. Methods: Between 2011 and 2018, patients with the DCM clinical spectrum and documented SVA, suspected SVA, or considered to be at intermediate or high risk for SVA were enrolled in the prospective Leiden Nonischemic Cardiomyopathy Study. Patients underwent a comprehensive evaluation including 24-hour Holter, LGE-CMR, and electrophysiology study. Holters were assessed for the presence of NSVT (≥3 beats; rate, ≥120 bpm; lasting 0.05). During 4.0±1.8 years of follow-up, SVA occurred in 39 patients (34%). NSVT (HR, 4.47 [95% CI, 1.87–10.72]; P =0.001) and VT inducibility (HR, 3.08 [95% CI, 1.08–8.81]; P =0.036) were independently associated with SVA during follow-up. A bivariable model including only noninvasively acquired parameters also allowed identification of a high-risk subgroup (ie, those with both NSVT and LGE on CMR). The findings remained similar when only patients without prior SVA were included. Conclusions: In patients with DCM, NSVT on Holter and VT inducibility during electrophysiology study predict SVA during follow-up independent of LGE on CMR. NSVTs may serve as an initiator, and sustained VT inducibility indicates the presence of the substrate for SVA in DCM. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01940081.
- Open Access
- 13 November 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (2) , 328-338
Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
- 13 November 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (2) , 328-338
Open AccessMajor bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
- Open Access
- 19 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 92-103
Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
- 19 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 92-103
Open AccessInter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
- Open Access
- 13 October 2021
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (7) , e12597
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
- 13 October 2021
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (7) , e12597
Open AccessStability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
- 6 November 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (1) , 46-51
Multi‐dose drug dispensing as a tool to improve medication adherence: A study in patients using vitamin K antagonists
Purpose: Multi‐dose drug dispensing (MDD) is a dosing aid that provides patients with disposable bags containing all drugs intended for 1 dosing moment. MDD is believed to increase medication adherence, but studies are based on self‐reported data, and results may depend on socially desirable answers. Therefore, our purpose was to determine the effect of MDD on medication adherence in non‐adherent patients taking vitamin K antagonists (VKAs), and to compare with instructing patients on medication use.Methods: We conducted a before‐after study in non‐adherent patients where MDD was the exposure and change in adherence after MDD initiation was the outcome (within patient comparison). Time in therapeutic range (TTR) was selected as a measure for adherence, as this reflects stability of VKA treatment. To analyze whether MDD improved adherence as compared with standard care (ie, letters or calls from nurses of the anticoagulation clinic), non‐adherent patients without MDD were also followed to estimate their TTR change over time (between patient comparison).Results: Eighty‐three non‐adherent VKA patients started using MDD. The median TTR was 63% before MDD and 73% 6 months after MDD. The within patient TTR increased on average by 13% (95%CI 6% to 21%) within 1 month after starting MDD and remained stable during the next 5 months. The TTR of MDD‐patients increased 10% (95%CI 2% to 19%) higher as compared with non‐MDD patients within 1 month but was similar after 4 months (TTR difference 3%, 95%CI –2% to 9%).Conclusions: Adherence improved after initiation of MDD. Compared with instructing patients, MDD was associated with better adherence within 1 month but was associated with similar improvement after 4 months.
- 6 November 2017
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 27 (1) , 46-51
Multi‐dose drug dispensing as a tool to improve medication adherence: A study in patients using vitamin K antagonists
Purpose: Multi‐dose drug dispensing (MDD) is a dosing aid that provides patients with disposable bags containing all drugs intended for 1 dosing moment. MDD is believed to increase medication adherence, but studies are based on self‐reported data, and results may depend on socially desirable answers. Therefore, our purpose was to determine the effect of MDD on medication adherence in non‐adherent patients taking vitamin K antagonists (VKAs), and to compare with instructing patients on medication use.Methods: We conducted a before‐after study in non‐adherent patients where MDD was the exposure and change in adherence after MDD initiation was the outcome (within patient comparison). Time in therapeutic range (TTR) was selected as a measure for adherence, as this reflects stability of VKA treatment. To analyze whether MDD improved adherence as compared with standard care (ie, letters or calls from nurses of the anticoagulation clinic), non‐adherent patients without MDD were also followed to estimate their TTR change over time (between patient comparison).Results: Eighty‐three non‐adherent VKA patients started using MDD. The median TTR was 63% before MDD and 73% 6 months after MDD. The within patient TTR increased on average by 13% (95%CI 6% to 21%) within 1 month after starting MDD and remained stable during the next 5 months. The TTR of MDD‐patients increased 10% (95%CI 2% to 19%) higher as compared with non‐MDD patients within 1 month but was similar after 4 months (TTR difference 3%, 95%CI –2% to 9%).Conclusions: Adherence improved after initiation of MDD. Compared with instructing patients, MDD was associated with better adherence within 1 month but was associated with similar improvement after 4 months.